CVKD · XBRL financial data
Cadrenal Therapeutics financial statements, every fiscal year
The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CVKD's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Cost of goods and services sold | — | 220 | — | — |
| Research and development | — | 4,081 | 4,205 | 4,100 |
| General and administrative | — | 3,550 | 6,754 | 9,354 |
| Total operating expenses | — | 7,633 | 10,961 | 13,461 |
| Operating income (loss) | — | (7,633) | (10,961) | (13,461) |
| Interest expense | — | 4 | — | — |
| Net income (loss) | — | (8,357) | (10,651) | (13,237) |
| Earnings per share, basic USD per share | — | (0.62) | (8.73) | (6.64) |
| Earnings per share, diluted USD per share | — | (0.62) | (8.73) | (6.64) |
| Weighted average shares, basic thousands of shares | — | 13,492 | 1,220 | 1,994 |
| Weighted average shares, diluted thousands of shares | — | 13,492 | 1,220 | 1,994 |
Balance sheet
CSVFiscal years (CVKD's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | 33 | 8,403 | 10,000 | 4,008 |
| Prepaid and other current assets | — | 52 | 42 | 200 |
| Total current assets | 728 | 8,492 | 10,113 | 4,319 |
| Property and equipment, net | 1 | 2 | 7 | 5 |
| Right-of-use asset | 44 | 21 | — | — |
| Total assets | 778 | 8,519 | 10,124 | 4,327 |
| Accounts payable | 405 | 167 | 1,502 | 651 |
| Accrued liabilities | 864 | 638 | 1,181 | 937 |
| Total current liabilities | 1,334 | 827 | 2,684 | 1,588 |
| Lease liability, non-current | 21 | — | — | — |
| Total liabilities | 6,329 | 827 | 2,684 | 1,588 |
| Accumulated deficit | (6,714) | (15,071) | (25,723) | (38,960) |
| Total stockholders' equity | (5,551) | 7,692 | 7,440 | 2,739 |
| Total liabilities and equity | 778 | 8,519 | 10,124 | 4,327 |
| Common shares outstanding (cover page) thousands of shares | 11,635 | 16,008 | 1,880 | 2,507 |
Cash flows
CSVFiscal years (CVKD's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Net income (loss) | — | (8,357) | (10,651) | (13,237) |
| Stock-based compensation | — | 710 | 1,419 | 1,940 |
| Net cash from operating activities | — | (3,530) | (7,358) | (12,602) |
| Purchases of property and equipment | — | 3 | 7 | 5 |
| Net cash from investing activities | — | (3) | (7) | (5) |
| Proceeds from issuing common stock | — | — | 5,144 | 4,862 |
| Net cash from financing activities | — | 11,903 | 8,980 | 6,597 |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Cadrenal Therapeutics | 2,388 | not reported | (2,233)* | 3.6M | 1.1 quarters | 10-QJun 30, 2026 |
| Curis | 5,073 | 0 | (9,646)* | 2.1M | 0.5 quarters | 10-QJun 30, 2026 |
| Kala Bio | 229 | not reported | (1,535)* | 19.3M | 4.7 quarters | 10-QJun 30, 2026 |
| Lexaria Bioscience | 3,500 | 0 | (1,635)* | 24.8M | 2.2 quarters | 10-QMay 31, 2026 |
| Pulmatrix | 2,168 | not reported | (1,106)* | 3.7M | 2.0 quarters | 10-QJun 30, 2026 |
| Dyadic International | 1,425 | 961 | (1,818)* | 36.4M | 1.7 quarters | 10-QJun 30, 2026 |
| Scynexis | 10,487 | 235 | (14,885)* | 9.9M | 3.6 quarters | 10-QJun 30, 2026 |
| Palatin Technologies | 7,492 | 301* | (2,690)* | 1.8M | 2.8 quarters | 10-KJun 30, 2026 |
| Aytu Biopharma | 26,308 | 16,106* | 4,406* | 10.9M | — | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.